Pàgina inicial > Resultats de la cerca: Blauvelt, A.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 5 registres trobats en 0.04 segons.
Articles, 5 registres trobats
Articles 5 registres trobats  
1.
18 p, 504.6 KB Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure / Armstrong, April W (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ; Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Boehncke, Wolf-Henning (University of Geneva. Department of Pathology and Immunology) ; Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ; Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ; Papp, Kim (K Papp Clinical Research and Probity Medical Research) ; Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ; Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ; Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ; Renda, Lisa (Eli Lilly and Company) ; Agada, Noah (Eli Lilly and Company) ; Xu, Wen (Eli Lilly and Company) ; Gallo, Gaia (Eli Lilly and Company) ; Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ; Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150  
Registre complet - Creative Commons
2.
13 p, 3.0 MB Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase clinical trials (re 1 and re 2) through 148 weeks / Reich, Kristian (Dermatologikum Berlin) ; Warren, R. B. (The University of Manchester. Manchester NIHR Biomedical Research Centre. Salford Royal NHS Foundation Trust) ; Iversen, Lars (Aarhus University Hospital (Aarhus, Dinamarca)) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Pau-Charles, I. (Almirall R&D) ; Igarashi, A. (NTT Medical Center Tokyo) ; Ohtsuki, M. (Jichi Medical University) ; Falqués, M. (Almirall R&D) ; Harmut, M. (Almirall R&D) ; Rozzo, S. (Sun Pharmaceuticals) ; Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ; Cantrell, W. (University of Alabama at Birmingham) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Thaçi, Diamant (University of Lübeck) ; Universitat Autònoma de Barcelona
Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. [...]
2019 - 10.1111/bjd.18232
British journal of dermatology, Vol. 182 (july 2019) , p. 605-617  
Registre complet - Creative Commons
3.
5 p, 332.3 KB Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study / Thaçi, Diamant (Research Institute and Comprehensive Center for Inflammation Medicine. University of Luebeck) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Reich, Kristian (Dermatologikum Berlin and SCIderm Research Institute) ; Tsai, T. F. (National Taiwan University Hospital (Taipei, Taiwan)) ; Tyring, S. (University of Texas Health Science Center and Center for Clinical Studies) ; Kingo, K. (Tartu University Hospital (Tartu, Estònia)) ; Ziv, M. (Emek Medical Center) ; Pinter, A. (Department of Dermatology. University of Frankfurt) ; Vender, Ronald (Venderm Innovations in Psoriasis) ; Lacombe, A. (Novartis Pharma AG) ; Xia, Shang (Novartis Beijing Novartis Pharma Co Ltd) ; Bhosekar, V. (Novartis Healthcare Pvt Ltd) ; Gilloteau, I. (Novartis Pharma AG) ; Guana, A. (Novartis Pharmaceuticals Corporation) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Universitat Autònoma de Barcelona
2019 - 10.1016/j.jaad.2019.04.045
Journal of the American Academy of Dermatology, Vol. 81 Núm. 6 (december 2019) , p. 1405-1409  
Registre complet - Creative Commons
4.
1 p, 320.3 KB Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) / Blauvelt, Andrew (SW Locust St., Suite G, Portland, OR 97223 USA) ; Papp, Kim A. (Waterloo, Canada) ; Griffiths, Christopher E. M. (Manchester, UK) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ; Dutronc, Yves (Indianapolis, IN USA) ; Kerr, Lisa Farmer (Indianapolis, IN USA) ; Ilo, Dapo (Indianapolis, IN USA) ; Mallbris, Lotus (Indianapolis, IN USA) ; Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ; Universitat Autònoma de Barcelona
2018 - 10.1007/s40257-018-0353-x
American Journal of Clinical Dermatology, Vol. 19 (march 2018) , p. 457  
Registre complet - Creative Commons
5.
8 p, 420.3 KB Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders : a Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) / Blauvelt, Andrew (SW Locust St., Suite G, Portland, USA) ; Papp, Kim A. (Waterloo, Canada) ; Griffiths, Christopher E. M. (Manchester, UK) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ; Dutronc, Yves (Indianapolis, IN USA) ; Kerr, Lisa Farmer (Indianapolis, IN USA) ; Ilo, Dapo (Indianapolis, IN USA) ; Mallbris, Lotus (Indianapolis, IN USA) ; Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ; Universitat Autònoma de Barcelona
Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. [...]
2017 - 10.1007/s40257-016-0246-9
American Journal of Clinical Dermatology, Vol. 18 (january 2017) , p. 273-280  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
7 Blauvelt, Andrew
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem